Full-Time

Art Supervisor

DTC/pharma agency exp required

Updated on 8/24/2026

EVERSANA

EVERSANA

1,001-5,000 employees

Commercial services for pharmaceutical lifecycle management

Compensation Overview

$90.6k - $131k/yr

New York, NY, USA

Remote

Bachelor's

Category
UI/UX & Design (1)
Required Skills
Adobe Creative Suite
Figma

Get referred to EVERSANA

See people who can refer or advise you

Requirements
  • Education: Bachelor's degree in Graphic Design, Fine Arts, Advertising, or a related field.
  • 6+ years of design experience within an agency; 2-3 years of pharma experience is needed.
  • Creative Development: Proven ability to take full responsibility for concept and art/design development across various projects of differing complexity and scope.
  • Strategic Liaison: Experience acting as a direct liaison between creative teams and junior/mid-level account team members, ensuring strategic and creative expectations are met.
  • Regulatory Knowledge: Solid understanding of FDA regulations and pharmaceutical promotion requirements across all communication channels.
  • Marketing Principles: Intimate knowledge of marketing and advertising principles to ensure work achieves its full potential, adheres to brand standards, and provides a consistent brand experience across all channels.
  • Presentation Skills: Expertise in presenting and defending work both internally and externally.
  • Leadership: Demonstrated leadership capabilities, including monitoring the workload of direct reports and intervening when necessary to maintain quality and timelines.
  • Design/Art Direction: Ability to lead and elevate design and art direction across the team.
  • Must have DTC/DTP experience and be highly conceptual; Adobe Creative Suite is a must and Figma is ideal.
Responsibilities
  • The ability to lead and elevate art/design across the team, adding value wherever possible.
  • Adept at providing constructive feedback to more junior-level creatives, advancing the creative from both a copy and art standpoint.
  • Possesses strong conceptual skills with the ability to bring a wide range of creative solutions to every project.
  • Leads art direction across projects ranging in scope, complexity, and channel to create a cohesive brand experience that meets/exceeds expectations.
  • Proficient in estimating individual hours (for oneself and direct reports) for a variety of different projects.
  • Ability to use advanced design principals to distill complex scientific information and turn it into compelling, clear data visualizations for our brands.
  • Understands the importance of utilization and works hard to hit targets for themselves and direct reports.
  • Knowledge of accessibility best practices and a commitment to apply them to our work.
  • Mentors and grows junior team members, elevating their designs and expanding their industry knowledge.
  • Growing knowledge of our clients’ business and how our work impacts the business.
  • Proactively works in close concert with planning, UX, and development to ensure team alignment.
  • Develops strong relationships with creative, account management, product management, production, studio, and cross functional team members.
  • Confidently presents and helps sell ideas to our clients.
  • Volunteers to contribute to new business efforts.
  • Mastery in developing multichannel creative (within portfolio) that displays strong conceptual thinking, strategic/business acumen, and finely crafted designs.
  • A wide range of industry experience including launches, label updates, etc.
  • Demonstrate a commitment to diversity, equity, and inclusion through continuous development, modeling inclusive behaviors, and proactively managing bias.
  • All other duties as assigned

EVERSANA provides integrated commercial services to pharmaceutical and biotech companies across the product lifecycle. It helps with drug pricing, market access, reimbursement, patient adherence, and product delivery through a service-based model. Its solutions are delivered via a global network of 30+ locations, including consulting, market access strategies, patient services, and field deployment. The goal is to help clients bring products to market, optimize pricing and access, improve adherence, and ensure efficient delivery to improve patient outcomes and commercial performance.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Milwaukee, Wisconsin

Founded

2018

Get referred to EVERSANA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EVERSANA signed Candel Therapeutics and Xcovery launch deals in 2026, expanding pipeline.
  • Mike Guarino and Jen Norton appointments strengthen agency and market-access leadership in 2026.
  • August 20, 2026 platform expansion supports cross-sell into medical, commercial, and access teams.

What critics are saying

  • Integration risk remains high after the August 2025 Waltz merger and APACME carve-out.
  • Large clients can insource AI commercialization, shrinking EVERSANA's agency and services revenue in 2027.
  • If Candel's CAN-2409 launch or similar launches fail, EVERSANA loses marquee growth proof.

What makes EVERSANA unique

  • August 2026 AI Agency spans medical affairs, market research, field sales, and MLR automation.
  • EVERSANA combines commercialization, distribution, patient services, and payer connectivity inside one operating model.
  • The 2025 Waltz Health merger adds drug-pricing marketplaces and direct-to-payer capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 20th, 2026
EVERSANA expands AI-powered platform across medical affairs and commercial operations

EVERSANA has expanded its AI-powered commercialisation platform beyond marketing to include medical affairs, market research, and field sales team engagement. The platform, which combines agentic AI orchestration, workflow automation, and enterprise data capabilities, now offers solutions for medical information, market research, MLR automation, and analytics. The company is developing additional features for market access, patient services, and sales enablement. The platform aims to help life sciences organisations improve efficiency whilst maintaining industry compliance and governance requirements. "Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialisation," said Mark Thierer, EVERSANA's chief executive officer. The company serves more than 650 organisations globally. EVERSANA will showcase the platform at an event on 27 August in New York.

PR Newswire
Jun 9th, 2026
EVERSANA appoints Jen Norton as President of Market Access & Value to lead integrated business unit

EVERSANA, a global provider of commercial services to the life sciences industry, has appointed Jen Norton as President, Market Access & Value. Norton will lead a new dedicated market access business unit integrating EVERSANA's services across global pricing, revenue management, value and evidence, and consulting. Norton brings over 20 years of market access leadership experience. She joins from Takeda, where she served as Senior Vice President and Head of U.S. Patient and Market Access, and previously held senior positions at Amgen and Biogen. The new unit reinforces EVERSANA's commitment to helping clients navigate the complex pricing and access landscape. CEO Mark Thierer said successfully navigating market access is amongst the most critical challenges clients face today. EVERSANA serves over 650 organisations in the life sciences industry.

PR Newswire
May 6th, 2026
EVERSANA appoints Mike Guarino as CEO of global health agency EVERSANA INTOUCH

EVERSANA has appointed Mike Guarino as chief executive officer of EVERSANA INTOUCH, its global health agency. Guarino will lead strategy and operations across the agency's capabilities, focusing on integrating commercialisation opportunities through data and AI to deliver marketing solutions for life sciences clients. Guarino brings extensive agency experience, most recently serving as chief commercial officer at IPG Health. He spent over two decades in senior roles at FCB Health and co-founded Area 23. Senior leaders including Ann Cave, Susan Perlbachs, John Kenny and Dan Gandor will report to Guarino. Founder Faruk Capan will shift focus to expanding the company's AI Agency platform, launched in collaboration with Google in August 2025. EVERSANA provides commercial services to the life sciences industry, serving over 650 organisations globally.

PharmaLIVE
Apr 29th, 2026
Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy.

Candel Therapeutics announces commercial agreement with EVERSANA to support U.S. launch of prostate cancer therapy. Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement with EVERSANA, a provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer. Under the terms of the agreement, EVERSANA will provide Candel with a broad suite of integrated commercialization services including data and analytics, medical affairs, market access, and field operations. EVERSANA joins IDEA Pharma, a division of SAI MedPartners (IDEA), which has been providing path-to-market strategies and strategic positioning for aglatimagene. Candel has worked in close collaboration with both EVERSANA and IDEA on key pre-commercial workstreams as previously announced during Candel's virtual Research and Development Day in December 2025. This collaboration reflects Candel's deliberate approach to building a world class commercial organization with global reach, designed from the ground up and leveraging a team of highly experienced professionals poised to support the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer, subject to regulatory approval. This operating model gives Candel access to leading commercial capabilities while maintaining financial flexibility, capital efficiency, and scientific focus that has driven Candel's progress to date. "From the beginning, we designed Candel's commercial strategy around a partner-led model that allows us to stay focused on advancing the science and navigating the regulatory pathway, while having access to world-class commercial capabilities on demand," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "With the addition of EVERSANA, that model is fully in place, and with the progress we've already made across our pre-commercialization workstreams, we have confidence in our readiness for the potential commercial launch of aglatimagene for the treatment of intermediate- to high-risk, localized prostate cancer. We look forward to working with EVERSANA and IDEA Pharma in providing a novel and potentially invaluable therapeutic for localized prostate cancer patients." "We are proud to support Candel as it advances what could be a new and potentially transformative treatment option for patients with localized prostate cancer," said Gregory Skalicky, President of EVERSANA. "Candel's unique approach to commercialization, building a dedicated and flexible platform with specialized partners, rather than a fixed pharmaceutical infrastructure, is exactly the type of model EVERSANA was designed to support. We have already integrated our resources alongside the Candel team, with key commercial workstreams actively underway, and we look forward to helping ensure that aglatimagene reaches patients efficiently and effectively upon potential approval."

PR Newswire
Apr 27th, 2026
Xcovery partners with EVERSANA to expand US launch of lung cancer drug Ensacove

Xcovery Holdings has partnered with EVERSANA to support the US commercial launch of Ensacove (ensartinib), a novel therapy for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. Under the agreement, EVERSANA will provide comprehensive end-to-end commercialisation services, including market access and commercial and medical teams. Ensacove is a next-generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals and is now available in the United States. The partnership aims to expand patient access across the US by leveraging EVERSANA's commercialisation capabilities and experience in the life sciences industry. EVERSANA serves over 650 organisations globally, including pharmaceutical startups and established companies.